How to access Rystiggo from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient living with generalised myasthenia gravis (gMG) may receive a prescription for Rystiggo (rozanolixizumab-noli) from their treating neurologist or neuromuscular specialist. Rystiggo is FDA-approved for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, and it is manufactured by UCB. It is notable as one of the first FcRn antagonists with a specific MuSK-positive indication — an important advance because MuSK-positive gMG is a clinically distinct and often more severe subtype. Rystiggo is administered as a subcutaneous infusion. In Saudi Arabia, Rystiggo may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Rystiggo is administered as a weekly subcutaneous infusion over approximately 15 minutes for six weeks (one treatment cycle), with additional cycles initiated based on clinical response and symptom fluctuation. Eligibility typically requires confirmed AChR- or MuSK-antibody seropositivity, an MGFA clinical classification, and pre-treatment screening. Your treating neurologist confirms diagnosis, screening status, and the cycle plan per FDA labeling.
Is Rystiggo legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework. The pathway allows a Saudi-licensed physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.
For Rystiggo specifically, the application benefits from the subcutaneous infusion route — it can be administered in a clinic or an infusion centre, and each session is brief.
How the pathway works, step by step
- Consultation with your treating neurologist. AChR or MuSK antibody confirmation, gMG clinical diagnosis, MGFA classification, and pre-treatment screening.
- Administration facility identification. The administering facility must be equipped for subcutaneous infusions and to manage any reaction.
- SFDA named-patient application. Your physician files the application including clinical letter, patient identifier, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Rystiggo ships at 2–8°C with continuous temperature monitoring.
- Arrival and cycle administration. The licensed facility administers the six-weekly cycle; additional cycles per clinical response.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming gMG diagnosis, AChR or MuSK antibody positivity, MGFA class, and prior therapy history
- Verification of Saudi medical licence
- Identification of the administering facility
- Patient identifier
- Pre-treatment screening results and vaccination record
- Planned cycle schedule
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for FcRn-antagonist therapy.
Costs and timing
Rystiggo's US cash-pay reference price sits in a broad indicative range — the annualised treatment cost varies with cycle frequency but falls in the USD 400,000–600,000 range in US list pricing. International cold-chain logistics, SFDA documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for the first cycle after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rystiggo specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for SFDA review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation.
How does Rystiggo compare with Vyvgart for gMG? Both are FcRn antagonists. Vyvgart is approved specifically for AChR-antibody-positive gMG and is administered IV (one hour) or as a Hytrulo subcutaneous formulation. Rystiggo is approved for both AChR-antibody- and MuSK-antibody-positive gMG and is administered as a weekly 15-minute subcutaneous infusion in six-week cycles. Patients with MuSK-positive disease often have Rystiggo specifically considered because of the broader approved label.
What about MuSK-positive myasthenia gravis? MuSK-positive gMG tends to have a more severe bulbar and respiratory phenotype and typically responds less well to conventional acetylcholinesterase inhibitors (pyridostigmine). The availability of an FcRn antagonist approved for MuSK-positive disease is clinically meaningful for this subgroup.
Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse gMG biologic therapy on escalated review; we supply documentation but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Rystiggo coordination in Saudi Arabia.
Add me to the Rystiggo waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.